Novel study into breast cancer origins paves way for personalized treatment — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/03/140331084036.htm
source : http://www.sciencedaily.com/releases/2014/03/140331084036.htm
source : http://www.sciencedaily.com/releases/2014/02/140221150453.htm
The study, PREvention with a MEDiterranean Diet (PREDIMED) has recently shown the link between the Mediterranean diet and low levels of cardiovascular disease. The questionnaire used as a reference asked consumers how often they ate vegetables, pasta, rice and other dishes made with sofrito, but the beneficial compounds of this product had never been analysed. Now researchers from the University of Barcelona (UB) and the Biomedical Research Centres Network — Physiopathology of Obesity and Nutrition (CIBERobn) of the Carlos III Health Institute, have for the first time identified polyphenols and carotenoids -healthy antioxidant substances- in sofrito, by using a high resolution mass spectrometry technique. The results have been published in the ‘Food Chemistry’ magazine and they show the presence of at least 40 types of polyphenols. …
The authors analyzed the genome of tumor cells at the onset of the disease and within several years after treatment, when the relapses occur. Thus, it has been possible to evaluate the genomic modifications associated with disease progression. These analyses have discovered the implication of several genes in the progression of these lymphomas and some mechanisms generating resistance to chemotherapy. …
A national team of researchers has analysed the risk that women diagnosed with a first case of invasive breast cancer face of developing a second primary cancer in a part of the body other than the breast. The results, published in the journal Gynecologic Oncology, indicate that this risk is 39% higher. María José Sánchez, co-author of the study and director of the Granada Cancer Register explained to SINC that the team’s study is the first populational study ever conducted in Spain to examine this associated risk. According to the study’s data, women under the age of 50 who had previously suffered from breast cancer were almost twice as likely to develop a second cancer than the general population (the risk was 96% greater). …
To look at the relationship between breast cancer and certain aspects of pregnancy and breastfeeding, Emilio González-Jiménez, PhD, of the University of Granada in Spain, and his colleagues analyzed the medical records of 504 female patients who were 19 to 91 years of age and who had been diagnosed and treated for breast cancer from 2004 to 2009 at the San Cecilio University Hospital in Granada. …
Now, in this week’s issue of Cell Stem Cell, the Salk Institute’s Juan Carlos Izpisua Belmonte and his colleagues show that the recipe for iPSCs is far more versatile than originally thought. For the first time, they have replaced a gene once thought impossible to substitute, creating the potential for more flexible recipes that should speed the adoption of stem cells therapies…
The PREDIMED nutrition trial based in Spain looked at the effect on the primary prevention of cardiovascular disease of over 7000 older people (aged 55 to 90) randomized to a Mediterranean Diet supplemented with extra virgin olive oil or nuts, compared to a control group following a low fat diet. In Mediterranean regions, nut consumption is relatively high compared to other countries…
At the meeting Prof Sung Hoon Noh, a gastric surgeon from Yonsei University College of Medicine, Korea, presented 5-year follow-up from the phase III CLASSIC trial, which added combination chemotherapy to a standard surgical procedure called D2 gastrectomy. The chemotherapy regimen studied in the trial is called XELOX, which is a combination of the drugs capecitabine and oxaliplatin. …
If caught early, melanoma is relatively easy to treat. But in its late stages, it is a stubborn and deadly cancer. Until about a decade ago, patients survived only about seven months after starting treatment. Since then, therapies, such as vemurafenib, that specifically target signaling proteins essential to the proliferation and survival of melanoma cells have extended the lives of some patients. …